[CAS NO. 150-38-9] Ethylenediaminetetraacetic acid trisodium salt

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [150-38-9]

Catalog

HY-B1009

Brand

MCE

CAS

150-38-9

DESCRIPTION [150-38-9]

Overview

MDL	MFCD00013305
Molecular Weight	358.19
Molecular Formula	C10H13N2Na3O8
SMILES	O=C(O)CN(CCN(CC(O[Na])=O)CC(O[Na])=O)CC(O[Na])=O

For research use only. We do not sell to patients.

5 Publications Citing Use of MCE

Summary

Ethylenediaminetetraacetic acid trisodium salt (EDTA trisodium salt) is used to bind metal ions in the practice of chelation therapy, for treating mercury and lead poisoning, used in a similar manner to remove excess iron from the body, for treating the complication of repeated blood transfusions, as would be applied to treat thalassaemia.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04310254	Istanbul Medipol University Hospital	Postoperative Pain\|Endodontically Treated Teeth	September 1, 2019	Not Applicable
NCT04067245	University Health Network, Toronto	Catheter Complications	April 1, 2019	Not Applicable
NCT05170932	Ain Shams University	Periodontal Bone Loss	January 2017	Not Applicable
NCT04893577	University of Utah	Herpes Simplex Oral	January 20, 2022	Phase 2
NCT00044213	Mt. Sinai Medical Center, Miami\|National Heart, Lung, and Blood Institute (NHLBI)\|National Center for Complementary and Integrative Health (NCCIH)	Coronary Artery Disease	September 2003	Phase 3
NCT02714075	Swiss Federal Institute of Technology\|University for Development Studies, Tamale, Ghana	Iron Deficiency and+or Anemia	April 2016	Not Applicable
NCT03336970	Mehmet Kemal �al??kan\|Ege University	Root Canal Infection	January 1, 2011	Not Applicable
NCT04559334	Boston Children´s Hospital\|SterileCare Inc.	Central Line Complication\|Central Line-associated Bloodstream Infection (CLABSI)	December 21, 2020	Not Applicable
NCT03419429	Ain Shams University	Chronic Periodontitis	January 2016	Phase 4
NCT02286258	Assistance Publique - Hôpitaux de Paris\|Ministry of Health, France	Renal Insufficiency, Chronic\|Kidney Diseases	October 2014	Phase 1\|Phase 2
NCT01118663	Cumberland Pharmaceuticals	Acetaminophen Overdose	September 2010	Phase 3
NCT03424746	Mt. Sinai Medical Center, Miami	Critical Limb Ischemia\|Peripheral Arterial Disease	August 2015	Early Phase 1
NCT03853200	Dow University of Health Sciences	Endodontic Disease\|Root Canal Infection	April 3, 2017	Phase 2\|Phase 3
NCT04044417	Ain Shams University	Periodontitis	August 25, 2016	Phase 4
NCT00227409	Chang Gung Memorial Hospital	Urologic Disease	November 2001	Not Applicable
NCT00237952	Chang Gung Memorial Hospital	Diabetic Nephropathies\|Diabetes Mellitus, Type II	August 2005	Not Applicable
NCT04980066	Kafrelsheikh University	Gingival Recession	August 3, 2021	Not Applicable
NCT02733185	Mt. Sinai Medical Center, Miami\|National Center for Complementary and Integrative Health (NCCIH)\|National Heart, Lung, and Blood Institute (NHLBI)\|Duke Clinical Research Institute	Diabetes\|Myocardial Infarction	October 2016	Phase 3
NCT04154553	University Hospital, Basel, Switzerland\|Toppharm Apotheke Hersberger, Spalenberg 41, CH-4051 Basel	Adverse Drug Reaction\|Therapy Failure	October 15, 2019
NCT05064462	Assistance Publique - Hôpitaux de Paris\|BioMérieux	Heart Transplant Rejection\|Heart Transplant Infection\|Virus	March 3, 2022
NCT00757458	University of Sao Paulo\|AstraZeneca	Drug Contamination	December 2008	Not Applicable
NCT01950975	Centre Hospitalier Universitaire Dijon	Malformations With Skin Manifestations Suggesting Mosaicism		Not Applicable
NCT03985371	University of Rochester\|Livionex Inc	Corneal Dystrophy, Band-Shaped	June 29, 2020	Early Phase 1
NCT03253393	The University of New South Wales\|Menicon Co., Ltd.	Optometry	June 4, 2018	Not Applicable
NCT04786327	Tanta University	Periodontal Regeneration	January 1, 2018	Phase 2
NCT04548713	Fraser Health\|SterileCare Inc.\|Center for Health Evaluation & Outcome Services	Central Venous Catheter Thrombosis\|Central Venous Catheter Related Bloodstream Infection\|Catheter Complications\|Catheter Blockage\|Catheter Dysfunction\|Central Line-associated Bloodstream Infection (CLABSI)\|Catheter\|Catheter Infection	March 22, 2022	Not Applicable

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : 50 mg/mL ( 139.59 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7918 mL	13.9591 mL	27.9181 mL
5 mM	0.5584 mL	2.7918 mL	5.5836 mL
10 mM	0.2792 mL	1.3959 mL	2.7918 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 50 mg/mL (139.59 mM); Clear solution; Need ultrasonic

* All of the co-solvents are available by MCE.

Synonyms

Glycine, N,N′-1,2-ethanediylbis[N-(carboxymethyl)-, sodium salt (1:3)

Acetic acid, (ethylenedinitrilo)tetra-, trisodium salt

Glycine, N,N′-1,2-ethanediylbis[N-(carboxymethyl)-, trisodium salt

EDTA trisodium salt

Perma Kleer 50, trisodium salt

Sequestrene trisodium

Sequestrene trisodium salt

Trilon AO

Trisodium edetate

Trisodium hydrogen ethylenediaminetetraacetate

Trisodium hydrogen (ethylenedinitrilo)tetraacetate

Trisodium versenate

Versene 9

Ethylenediaminetetraacetic acid trisodium salt

Nevanaid-B powder

Trisodium ethylenediaminetetraacetate

Sequestrene Na₃

Edetate trisodium

Trisodium EDTA

Clewat 300A

Trisodium ETDA

Chelest C

Limclair

Sequestrene NA 3T

EDTA-3Na

Chelest 2CS

Chelate C

Zonon T

Chelest 2C-SD

Clewat 3Na

EDTA trisodium